Heart Institute, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
Erasmus University Medical Center, Amsterdam, the Netherlands.
JACC Cardiovasc Interv. 2016 Dec 26;9(24):2481-2489. doi: 10.1016/j.jcin.2016.10.008.
The authors undertook a patient-level meta-analysis to compare long-term outcomes after coronary artery bypass grafting (CABG) versus percutaneous coronary intervention (PCI) with drug-eluting stents (DES) in 3,280 patients with left main or multivessel coronary artery disease (CAD).
The relative efficacy and safety of CABG versus PCI with DES for left main or multivessel CAD remain controversial.
Data were pooled from the BEST (Randomized Comparison of Coronary Artery Bypass Surgery and Everolimus Eluting Stent Implantation in the Treatment of Patients With Multivessel Coronary Artery Disease), PRECOMBAT (Premier of Randomized Comparison of Bypass Surgery vs. Angioplasty Using Sirolimus-Eluting Stent in Patients With Left Main Coronary Artery Disease), and SYNTAX (Synergy Between PCI With Taxus and Cardiac Surgery) trials. The primary outcome was a composite of all-cause death, myocardial infarction, or stroke.
The median follow-up was 60 months, and follow-up was completed for 96.2% of patients. The rate of primary outcome was significantly lower with CABG than with PCI (13.0% vs. 16.0%; hazard ratio [HR]: 0.83; 95% confidence interval [CI]: 0.69 to 1.00; p = 0.046). The difference was mainly driven by reduction in myocardial infarction (HR: 0.46; 95% CI: 0.33 to 0.64; p < 0.001). There was significant interaction between treatment effect and types of CAD, showing CABG to be superior compared with PCI with DES in patients with multivessel CAD (p = 0.001), but no between-group difference in those with left main CAD (p = 0.427). The rates for all-cause death and stroke were similar between the 2 groups. By contrast, the need for repeat revascularization was significantly lower in the CABG group compared with the PCI group.
CABG, as compared with PCI with DES, reduced long-term rates of the composite of all-cause death, myocardial infarction, or stroke in patients with left main or multivessel CAD. The advantage of CABG over PCI with DES was particularly pronounced in those with multivessel CAD.
作者对 3280 例左主干或多支血管冠状动脉疾病(CAD)患者进行了患者水平的荟萃分析,比较了冠状动脉旁路移植术(CABG)与药物洗脱支架(DES)经皮冠状动脉介入治疗(PCI)的长期结果。
CABG 与 DES 治疗左主干或多支 CAD 的相对疗效和安全性仍存在争议。
数据来自 BEST(随机比较冠状动脉旁路移植术和依维莫司洗脱支架治疗多支血管 CAD 患者)、PRECOMBAT(左主干 CAD 患者经皮冠状动脉旁路移植术与依维莫司洗脱支架的初步比较)和 SYNTAX(紫杉醇 PCI 与心脏手术的协同作用)试验。主要结局是全因死亡、心肌梗死或卒中等复合终点。
中位随访时间为 60 个月,96.2%的患者完成了随访。CABG 组的主要结局发生率明显低于 PCI 组(13.0%比 16.0%;风险比 [HR]:0.83;95%置信区间 [CI]:0.69 至 1.00;p=0.046)。差异主要归因于心肌梗死发生率的降低(HR:0.46;95%CI:0.33 至 0.64;p<0.001)。治疗效果与 CAD 类型之间存在显著交互作用,表明 CABG 优于 DES 治疗多支 CAD 患者(p=0.001),但在左主干 CAD 患者中无组间差异(p=0.427)。两组间全因死亡和卒中等的发生率相似。相比之下,CABG 组需要再次血运重建的比例明显低于 PCI 组。
与 DES 治疗相比,CABG 降低了左主干或多支 CAD 患者全因死亡、心肌梗死或卒中的复合发生率。CABG 优于 DES 治疗的优势在多支 CAD 患者中更为显著。